Gene Page: PRG2
Summary ?
| GeneID | 5553 |
| Symbol | PRG2 |
| Synonyms | BMPG|MBP|MBP1 |
| Description | proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule major basic protein) |
| Reference | MIM:605601|HGNC:HGNC:9362|Ensembl:ENSG00000186652|HPRD:09283|Vega:OTTHUMG00000167027 |
| Gene type | protein-coding |
| Map location | 11q12 |
| Pascal p-value | 1.05E-4 |
| Sherlock p-value | 0.572 |
| DMG | 1 (# studies) |
Gene in Data Sources
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:PGCnp | Genome-wide Association Study | GWAS | |
| DMG:Wockner_2014 | Genome-wide DNA methylation analysis | This dataset includes 4641 differentially methylated probes corresponding to 2929 unique genes between schizophrenia patients (n=24) and controls (n=24). | 1 |
Section I. Genetics and epigenetics annotation
Differentially methylated gene
| Probe | Chromosome | Position | Nearest gene | P (dis) | Beta (dis) | FDR (dis) | Study |
|---|---|---|---|---|---|---|---|
| cg15357945 | 11 | 57158361 | PRG2 | 5.85E-5 | -0.503 | 0.023 | DMG:Wockner_2014 |
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| MARCKSL1 | 0.94 | 0.92 |
| FAM110A | 0.94 | 0.85 |
| SHF | 0.93 | 0.83 |
| DBN1 | 0.93 | 0.85 |
| DCAF15 | 0.93 | 0.85 |
| SIRT6 | 0.93 | 0.83 |
| AKT1 | 0.93 | 0.86 |
| ZNF821 | 0.93 | 0.82 |
| TUBB3 | 0.93 | 0.84 |
| NKIRAS2 | 0.93 | 0.85 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| C5orf53 | -0.74 | -0.76 |
| HLA-F | -0.72 | -0.71 |
| CA4 | -0.71 | -0.77 |
| AF347015.27 | -0.69 | -0.76 |
| AF347015.31 | -0.68 | -0.76 |
| AF347015.33 | -0.68 | -0.76 |
| S100B | -0.67 | -0.71 |
| PLA2G4A | -0.67 | -0.74 |
| ALDOC | -0.67 | -0.63 |
| MT-CO2 | -0.66 | -0.75 |
Section V. Pathway annotation
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| KEGG ASTHMA | 30 | 25 | All SZGR 2.0 genes in this pathway |
| GAZDA DIAMOND BLACKFAN ANEMIA ERYTHROID DN | 493 | 298 | All SZGR 2.0 genes in this pathway |
| CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN | 663 | 425 | All SZGR 2.0 genes in this pathway |
| TONKS TARGETS OF RUNX1 RUNX1T1 FUSION HSC DN | 187 | 115 | All SZGR 2.0 genes in this pathway |
| GRAHAM CML DIVIDING VS NORMAL QUIESCENT UP | 181 | 101 | All SZGR 2.0 genes in this pathway |
| GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING DN | 87 | 49 | All SZGR 2.0 genes in this pathway |
| LINDGREN BLADDER CANCER CLUSTER 1 DN | 378 | 231 | All SZGR 2.0 genes in this pathway |
| DUNNE TARGETS OF AML1 MTG8 FUSION UP | 52 | 32 | All SZGR 2.0 genes in this pathway |
| PARK HSC VS MULTIPOTENT PROGENITORS DN | 18 | 12 | All SZGR 2.0 genes in this pathway |
| BYSTROEM CORRELATED WITH IL5 UP | 51 | 30 | All SZGR 2.0 genes in this pathway |
| HADDAD T LYMPHOCYTE AND NK PROGENITOR UP | 78 | 56 | All SZGR 2.0 genes in this pathway |
| NAKAJIMA MAST CELL | 46 | 34 | All SZGR 2.0 genes in this pathway |
| MA MYELOID DIFFERENTIATION UP | 39 | 29 | All SZGR 2.0 genes in this pathway |
| RADMACHER AML PROGNOSIS | 78 | 52 | All SZGR 2.0 genes in this pathway |
| KUMAR TARGETS OF MLL AF9 FUSION | 405 | 264 | All SZGR 2.0 genes in this pathway |
| KRIGE RESPONSE TO TOSEDOSTAT 6HR UP | 953 | 554 | All SZGR 2.0 genes in this pathway |
| KRIGE RESPONSE TO TOSEDOSTAT 24HR DN | 1011 | 592 | All SZGR 2.0 genes in this pathway |
| KYNG DNA DAMAGE BY GAMMA RADIATION | 81 | 59 | All SZGR 2.0 genes in this pathway |
| KYNG DNA DAMAGE UP | 226 | 164 | All SZGR 2.0 genes in this pathway |
| KONDO PROSTATE CANCER WITH H3K27ME3 | 196 | 93 | All SZGR 2.0 genes in this pathway |
| SMID BREAST CANCER BASAL UP | 648 | 398 | All SZGR 2.0 genes in this pathway |
| BOYLAN MULTIPLE MYELOMA C D DN | 252 | 155 | All SZGR 2.0 genes in this pathway |
| YOSHIMURA MAPK8 TARGETS UP | 1305 | 895 | All SZGR 2.0 genes in this pathway |
| HOFMANN MYELODYSPLASTIC SYNDROM HIGH RISK DN | 20 | 13 | All SZGR 2.0 genes in this pathway |
| BOYAULT LIVER CANCER SUBCLASS G3 DN | 51 | 32 | All SZGR 2.0 genes in this pathway |
| BOYLAN MULTIPLE MYELOMA PCA1 UP | 101 | 66 | All SZGR 2.0 genes in this pathway |
| CAIRO LIVER DEVELOPMENT DN | 222 | 141 | All SZGR 2.0 genes in this pathway |
| MARTENS TRETINOIN RESPONSE DN | 841 | 431 | All SZGR 2.0 genes in this pathway |
| CHYLA CBFA2T3 TARGETS UP | 387 | 225 | All SZGR 2.0 genes in this pathway |
| NABA PROTEOGLYCANS | 35 | 23 | All SZGR 2.0 genes in this pathway |
| NABA CORE MATRISOME | 275 | 148 | All SZGR 2.0 genes in this pathway |
| NABA MATRISOME | 1028 | 559 | All SZGR 2.0 genes in this pathway |